Radiofrequency Ablation Devices Market size is valued at USD 3.5 billion in 2021 and is expected to reach USD 6.99 billion by 2028, at a CAGR of 10.3% during the forecast period 2022-2028. This report studies global radiofrequency ablation devices market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Radiofrequency ablation (RFA) is a procedure used to reduce pain and is also used to treat medical conditions such as cancer tumors with help of imaging techniques. An electrical current produced by a radio wave is used to heat up a small area of nerve tissue, thereby decreasing pain signals from that specific area. RFA can be used to help patients with chronic (long-lasting) low-back and neck pain and pain related to the degeneration of joints from arthritis. In July 2017, Stryker has announced that it has received FDA 510(k) clearance for its MultiGen 2 RF Generator. Medtronic introduced the OsteoCool RF Ablation device in Canada in April 2017 for the detection of bone metastases. This is the only dual-probe RF ablation device available, allowing for customized, adaptable, and predictable therapy.